Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2005 Nov;106(5 Pt 1):946-52.
doi: 10.1097/01.AOG.0000182576.48290.6d.

The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women

L Elaine Waetjen  1 , Jeanette S Brown, Eric Vittinghoff, Kristine E Ensrud, JoAnn Pinkerton, Robert Wallace, Judith L Macer, Deborah Grady
Affiliations
Randomized Controlled Trial

The effect of ultralow-dose transdermal estradiol on urinary incontinence in postmenopausal women

L Elaine Waetjen et al. Obstet Gynecol. 2005 Nov.

Abstract

Objective: To estimate the effect of 2 years of treatment with ultralow-dose transdermal estradiol (E2) on incontinence in postmenopausal women.

Methods: Ultra Low Dose Transdermal estRogen Assessment (ULTRA) was a multicenter, randomized, double-blinded, placebo-controlled trial of unopposed ultralow-dose (0.014 mg/d) transdermal E2 for prevention of osteoporosis in 417 postmenopausal women aged 60 to 80 years. Frequency of incontinence episodes was assessed at baseline and after 4 months and 2 years of treatment using a self-reported questionnaire. We used an intention-to-treat analysis to compare change in incontinence frequency, improved (decreased 2 or more episodes per week), unchanged (increased or decreased no more than 1 episode per week), or worsened (increased 2 or more episodes per week) between the E2 and placebo groups among women with and without at least weekly incontinence at baseline.

Results: At baseline, the prevalence of at least weekly incontinence was similar between E2 and placebo groups (43%). After 2 years, there was no difference between groups in the proportions of women with incontinence at baseline whose incontinence improved, worsened, or was unchanged. The odds ratio for worsening incontinence in the E2 compared with placebo group was 1.35 (95% confidence interval 0.75-2.42. In women without incontinence at baseline, the odds of developing at least weekly incontinence after 2 years in the E2 compared with placebo group was not significant (odds ratio 1.2, 95% confidence interval 0.7-2.2).

Conclusion: Two years of treatment with unopposed ultralow-dose transdermal E2 did not substantially change the frequency of incontinence symptoms or alter the risk of developing at least weekly incontinence.

Level of evidence: I.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flow chart detailing recruitment and retention of participants in the Ultra Low dose Transdermal estrogen Assessment (ULTRA) trial.
See this image and copyright information in PMC

References

    1. Fantl JA, Cardozo L, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee. Obstet Gynecol. 1994;83:12–8. - PubMed
    1. Elia G, Bergman A. Estrogen effects on the urethra: beneficial effects in women with genuine stress incontinence. Obstet Gynecol Surv. 1993;48:509–17. - PubMed
    1. Sacco F, Rigon G, Carbone A, Sacchini D. Transvaginal estrogen therapy in urinary stress incontinence [in Italian] Minerva Ginecol. 1990;42:539–44. - PubMed
    1. Jarmy-Di Bella ZI, Girao MJ, Sartori MF, Di Bella V, Junior, Lederman HM, Baracat EC, et al. Power Doppler of the urethra in continent or incontinent, pre- and postmenopausal women. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11:148–54. - PubMed
    1. Beisland HO, Fossberg E, Moer A, Sander S. Urethral sphincteric insufficiency in postmenopausal females: treatment with phenylpropanolamine and estriol separately and in combination. A urodynamic and clinical evaluation. Urol Int. 1984;39:211–6. - PubMed

Publication types